Oncology Scientific Publication 

Emerging molecular testing paradigms in NSCLC management

Prof. Frédérique Penault-Llorca

Prof. Frédérique Penault-Llorca
Prof. Mark Socinski

Prof. Mark Socinski
Publication Date

Apr 2025

info Summary and next episodes download Downloadable resources
Publication

We are pleased to announce that our recent literature review on emerging molecular testing in lung cancer, authored by Prof. Frédérique Penault-Llorca and Prof. Mark Socinski, has been published by The Oncologist.

 

The paper is titled:

 

Emerging molecular testing paradigms in NSCLC management - current perspectives and recommendations

 

For an overview of the publication, see the slides in the Downloadable Resources section.

 

The full publication can be accessed at: Emerging molecular testing paradigms in non-small cell lung cancer management—current perspectives and recommendations | The Oncologist | Oxford Academic

 

Clinical takeaways

  • Precision medicine in patient care requires specialised knowledge that is best delivered via a well-coordinated and well-educated MDT, up to date with the latest developments in lung biomarker research and testing technology  
  • Molecular testing should be performed in clinical situations where there is evidence that targeting particular molecular alterations makes a clinical difference  
  • Specimen acquisition and processing of tissue should follow well-established standard procedures and protocols. Genomic testing with NGS using multigene panels is highly recommended 
  • Besides methodological aspects, effective collaboration and communication within the MDT are paramount  
  • Patients should be evaluated by MDTs implementing rapid on-site evaluation (ROSE) and reflex testing to improve testing efficiency and reduce the time to treatment initiation 
    1. Have an awareness of the current biomarker landscape in lung cancer
    2. Understand the current testing strategies for precision oncology in lung cancer, associated challenges and how to implement these into clinical practice
    3. Explore potential future opportunities related to precision oncology for lung cancer

Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Frédérique PENAULT-LLORCA is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Frédérique PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Frédérique PENAULT-LLORCA has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.

Prof. Frédérique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Genomic Health, Gilead, GSK, Lilly, Menarini /Stemline, MERCK, MSD, Myriad, NanoString Technologies, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Servier, Tesaro; Institutional research grants from  AbbVie, Agendia, AstraZeneca, Bayer, BMS, Genomic Health, MSD, Myriad, NanoString Technologies, Roche; Congress invitations from AbbVie, AstraZeneca, BMS, MSD, Novartis, Pfizer, Roche 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Beigene, BMS, Cullinan, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis, OncoC4, Regeneron, Spectrum, Summit
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

We are pleased to announce that our recent literature review on emerging molecular testing in lung cancer, authored by Prof. Frédérique Penault-Llorca and Prof. Mark Socinski, has been published by The Oncologist.

 

The paper is titled:

 

Emerging molecular testing paradigms in NSCLC management - current perspectives and recommendations

 

For an overview of the publication, see the slides in the Downloadable Resources section.

 

The full publication can be accessed at: Emerging molecular testing paradigms in non-small cell lung cancer management—current perspectives and recommendations | The Oncologist | Oxford Academic

 

Clinical takeaways

  • Precision medicine in patient care requires specialised knowledge that is best delivered via a well-coordinated and well-educated MDT, up to date with the latest developments in lung biomarker research and testing technology  
  • Molecular testing should be performed in clinical situations where there is evidence that targeting particular molecular alterations makes a clinical difference  
  • Specimen acquisition and processing of tissue should follow well-established standard procedures and protocols. Genomic testing with NGS using multigene panels is highly recommended 
  • Besides methodological aspects, effective collaboration and communication within the MDT are paramount  
  • Patients should be evaluated by MDTs implementing rapid on-site evaluation (ROSE) and reflex testing to improve testing efficiency and reduce the time to treatment initiation 
  1. Have an awareness of the current biomarker landscape in lung cancer
  2. Understand the current testing strategies for precision oncology in lung cancer, associated challenges and how to implement these into clinical practice
  3. Explore potential future opportunities related to precision oncology for lung cancer

Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Frédérique PENAULT-LLORCA is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Frédérique PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Frédérique PENAULT-LLORCA has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.

Prof. Frédérique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Genomic Health, Gilead, GSK, Lilly, Menarini /Stemline, MERCK, MSD, Myriad, NanoString Technologies, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Servier, Tesaro; Institutional research grants from  AbbVie, Agendia, AstraZeneca, Bayer, BMS, Genomic Health, MSD, Myriad, NanoString Technologies, Roche; Congress invitations from AbbVie, AstraZeneca, BMS, MSD, Novartis, Pfizer, Roche 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Beigene, BMS, Cullinan, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis, OncoC4, Regeneron, Spectrum, Summit
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories, Boehringer Ingelheim, Eisai Pharma AG, Revolution Medicines, and AstraZeneca.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories, Boehringer Ingelheim, Eisai Pharma AG, Revolution Medicines, and AstraZeneca.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2026
LUNG CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Sep 2026
COR2ED
Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258
Explore all programmes